Metformin may protect against lung cancer

Sep 01, 2010

Metformin, a drug commonly used to treat type 2 diabetes, shows potential in the prevention of tobacco-induced lung tumors, according to early research conducted at the National Cancer Institute (NCI).

Metformin, a drug commonly used to treat , shows potential in the prevention of tobacco-induced lung tumors and possibly colorectal tumors, according to two studies published in Cancer Prevention Research.

The first study, conducted by researchers at the NCI, showed that metformin significantly decreased burden in mice exposed to a nicotine-derived nitrosamine called NNK, which is the most prevalent in tobacco. Researchers treated the mice with metformin either orally or by injection. Those treated orally had between 40 and 50 percent fewer tumors, while those mice treated with injection had 72 percent fewer tumors. Based on these findings, clinical trials of metformin are being considered to determine if this compound could be used as an effective chemoprevention agent for smokers at high risk of developing lung cancer.

A second study, conducted by researchers in Japan, showed, non-diabetics taking metformin had a significantly lower rate of rectal aberrant crypt foci, a surrogate marker of colorectal cancer. Patients in the treatment group had a mean of 5.11 foci compared with 7.56 in the control group.

Results of these studies were discussed at a teleconference hosted by Scott Lippman, M.D., editor-in-chief of Cancer Prevention Research, and professor and chair in the department of thoracic head and neck at the University of Texas M. D. Anderson Cancer Center on Wednesday, Sept. 1, 2010.

Metformin significantly decreased lung tumor burden in mice exposed to a nicotine-derived nitrosamine called NNK, which is the most prevalent carcinogen in tobacco. has been previously shown to activate an enzyme called AMP-activated protein kinase that is known to inhibit mTOR, a protein that regulates cell growth and survival in tobacco carcinogen-induced lung tumors.

Explore further: World first as viral immunotherapy for skin cancer shows patient benefit in phase III trial

Related Stories

Metformin may prevent lung cancer in smokers

Apr 19, 2010

Metformin, a mainstay of treatment for patients with type 2 diabetes, may soon play a role in lung cancer prevention if early laboratory research presented here at the AACR 101st Annual Meeting 2010 is confirmed in clinical ...

Penn researchers find diabetes drug kills some cancer cells

Aug 14, 2007

Researchers at the University of Pennsylvania School of Medicine have found that a commonly prescribed diabetes drug kills tumor cells that lack a key regulatory gene called p53. Results from current studies in mice may result ...

Recommended for you

Therapy-resistant breast cancer mechanism revealed

18 hours ago

Mitsuyoshi Nakao, Director of the Institute of Molecular Embryology and Genetics in Kumamoto University and Associate Professor Noriko Saitoh revealed that a cluster of defined, non-coding RNAs are mechanistically involved ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.